Repligen Co. (NASDAQ:RGEN) Shares Purchased by Verdence Capital Advisors LLC

Verdence Capital Advisors LLC boosted its position in shares of Repligen Co. (NASDAQ:RGEN) by 36.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,956 shares of the biotechnology company’s stock after buying an additional 793 shares during the period. Verdence Capital Advisors LLC’s holdings in Repligen were worth $531,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RGEN. Artisan Partners Limited Partnership increased its holdings in shares of Repligen by 11.3% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company’s stock valued at $247,558,000 after acquiring an additional 157,807 shares during the period. Wellington Management Group LLP increased its stake in Repligen by 2.1% in the third quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company’s stock valued at $222,075,000 after purchasing an additional 29,215 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Repligen by 13.0% in the third quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company’s stock valued at $190,117,000 after buying an additional 137,220 shares during the last quarter. Conestoga Capital Advisors LLC boosted its stake in shares of Repligen by 0.4% during the fourth quarter. Conestoga Capital Advisors LLC now owns 709,738 shares of the biotechnology company’s stock worth $127,611,000 after buying an additional 2,590 shares during the period. Finally, Parnassus Investments LLC purchased a new position in shares of Repligen during the third quarter worth about $87,475,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling

In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares in the company, valued at $4,699,889.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CEO Anthony Hunt sold 16,707 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the transaction, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the transaction, the vice president now owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock worth $5,039,532 in the last quarter. Company insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on RGEN shares. Stifel Nicolaus upped their price objective on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. KeyCorp boosted their target price on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $196.70.

Repligen Price Performance

Repligen stock opened at $157.48 on Tuesday. The company has a market cap of $8.79 billion, a P/E ratio of 218.73, a price-to-earnings-growth ratio of 5.15 and a beta of 1.02. Repligen Co. has a one year low of $110.45 and a one year high of $211.13. The business has a fifty day moving average of $187.16 and a two-hundred day moving average of $173.44. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 7.02.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The firm had revenue of $155.74 million during the quarter, compared to analysts’ expectations of $155.38 million. During the same quarter last year, the business earned $0.68 earnings per share. The business’s revenue for the quarter was down 16.6% compared to the same quarter last year. As a group, analysts predict that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.